Clinical trials: Resectable Hepatocellular Carcinoma
Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Cohort study to assess the impact of ctDNA detection in the follow-up and management of patients with hepatocellular carcinoma treated by TACE
- Conditions
- Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
- Trial name
- Mona-Lisa (NCT05390112)
- Testing
- DNA
- Where
- France
- Volunteers
- 167 people
- Sponsor
- University Hospital, Rouen
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is an observational study. All patients who meet the inclusion criteria of our previous Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable…
- Trial name
- MORNING-RWS (NCT07064681)
- Testing
- Surgery with and without the aid of Indocyanine Green (ICG)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- PLATIC (NCT04814043)
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
HCC
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
This study is a single-center, randomized controlled exploratory Phase II clinical trial, aiming to assess the efficacy and safety of sintilimab combined with lenvatinib and HAIC for two cycles followed by surgery compared with…
- Trial name
- NCT06904014
- Testing
- HAIC, Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Lei ZHAO
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ATTACH (NCT07239245)
- Testing
- Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE)
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Liver Cancer
National Registry and Blood Bank of Patients With Liver Cancer
RATIONALE: Gathering health information about patients with liver cancer over time may help doctors learn more about the disease and may help the study of cancer in the future.
- Trial name
- NCT00482365
- Testing
- biologic sample preservation procedure, medical chart review, Patient interview
- Where
- 3 sites in United States
- Volunteers
- 151 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency…
- Trial name
- NCT00617981
- Testing
- ThermoDox, 5% Dextrose Solution
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 701 people
- Sponsor
- Imunon
Hepatocellular Carcinoma, Solid Tumor
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients…
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
- Trial name
- MYCHELANGELO I (NCT05497453)
- Testing
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two
- Where
- 15 sites in United States, Hong Kong and 3 more
- Volunteers
- 24 people
- Sponsor
- Omega Therapeutics
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01239355
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine the safety and tolerability of neoadjuvant/adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with HCC.
- Trial name
- NCT04658147
- Testing
- Nivolumab, Relatlimab
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Primary Liver Cancer, Non-Resectable Hepatocellular Carcinoma
MRI-guided Holmium-166 Radioembolization
To investigate the safety and feasibility of a personalized Ho-166-PLLA-MS TARE approach by using MRI guidance in inoperable patients with HCC.
- Trial name
- EMERITUS-2 (NCT05609448)
- Testing
- MRI-guided radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy
- Trial name
- NCT04888546
- Testing
- Anlotinib hydrochloride capsules＋ TQB2450 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
This study aims to investigate the efficacy and safety of neoadjuvant therapy with Iparomlimab and Tuvonralimab Injection (anti-PD-1 and anti-CTLA-4 antibody combination) in patients with resectable hepatocellular carcinoma at…
- Conditions
- HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant Immunotherapy
- Trial name
- NCT07515469
- Testing
- Iparomlimab and Tuvonralimab
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Hepatocellular carcinoma patients are mostly diagnosed at locally advanced stage. Nowadays, hepatic artery interventional therapy and/or systemic therapy are the main treatments options for these patients.
- Trial name
- HAICPD1-HCC (NCT03869034)
- Testing
- HAIC+PD1, HAIC
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len)…
- Trial name
- NCT04967495
- Testing
- TACE combined with lenvatinib and iodion-125 seeds brachytherapy, TACE combined with lenvatinib
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of SBRT combined with cardonilizumab and lenvastinib in the treatment of unresectable hepatocellular carcinoma with portal vein tumor…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors
- Trial name
- NCT06040177
- Testing
- Cadonilimab, Stereotactic radiotherapy, Renvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Hepatocellular Carcinoma Non-resectable
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05608200
- Testing
- Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
HCC
A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
Major Objectives To evaluate the efficacy of HAIC combined with Iparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) plus bevacizumab as a conversion therapy in patients with potentially…
- Trial name
- NCT07119931
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00023946
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)